Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK.
Int J Lab Hematol. 2011 Apr;33(2):154-8. doi: 10.1111/j.1751-553X.2010.01261.x. Epub 2010 Sep 14.
The sensitivity of APTT reagents to deficiencies of factors VIII, IX, XI and XII varies because of their composition. The APTT is used as a screening test for these factors, and a deficiency should manifest with a prolongation to the APTT, which may trigger the need for specific factor assays to be performed.
The suitability of APTT reagents to detect mild deficiencies can be assessed by the analysis of the APTT of plasma, which has an increasing concentration of the factor in question. The APTT responsiveness can be determined from the intersection of the curve and the upper limit of the APTT normal reference range for that APTT reagent. We assessed the APTT responsiveness (in U/dl) to factors VIII, IX and XI of four APTT reagents; Actin FS (Siemens), Synthasil (IL), STA-PTTA (Stago) and Dapttin (Technoclone).
Actin FS was the most sensitive reagent to mild reductions of factors VIII, IX and XI [Correction added on 26 October 2010, after first online publication: Synthasil was corrected to Actin FS]. STA-PTTA showed less sensitivity than Synthasil and Actin FS; Dapttin was insensitive to mild deficiencies of factors IX and XI and should not be used as a screening test.
Both Synthasil and Actin FS are acceptable reagents to screen for reduced factors VIII, IX and XI, and the number of mildly reduced factors not diagnosed will be limited.
由于组成成分的不同,APTT 试剂对因子 VIII、IX、XI 和 XII 缺乏的敏感性存在差异。APTT 可作为这些因子的筛查试验,当存在缺乏时,APTT 会延长,这可能会引发需要进行特定因子检测。
通过分析含有递增浓度待测因子的血浆 APTT,可以评估 APTT 试剂检测轻度缺乏的适用性。APTT 反应性可通过曲线与该 APTT 试剂的 APTT 正常参考范围上限的交点来确定。我们评估了 4 种 APTT 试剂(Actin FS [西门子]、Synthasil [IL]、STA-PTTA [Stago]和 Dapttin [Technoclone])对因子 VIII、IX 和 XI 的 APTT 反应性(以 U/dl 表示)。
Actin FS 是最敏感的试剂,可检测到因子 VIII、IX 和 XI 的轻度减少[2010 年 10 月 26 日首次在线发表后更正:Synthasil 更改为 Actin FS]。STA-PTTA 比 Synthasil 和 Actin FS 的敏感性低;Dapttin 对因子 IX 和 XI 的轻度缺乏不敏感,不应作为筛查试验。
Synthasil 和 Actin FS 都是筛选因子 VIII、IX 和 XI 减少的可接受试剂,未诊断出的轻度减少因子的数量将受到限制。